bluebird bio, Inc. (0HOH.L)
USD 9.28
(33.91%)
USD 9.28
(33.91%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | -167.16 Million USD | 39.7% |
| 2022 | -215.55 Million USD | 48.6% |
| 2021 | -556.92 Million USD | 15.2% |
| 2020 | -553.63 Million USD | 21.42% |
| 2019 | -772.71 Million USD | -42.99% |
| 2018 | -551.86 Million USD | -69.87% |
| 2017 | -319.15 Million USD | -28.33% |
| 2016 | -254.47 Million USD | -59.0% |
| 2015 | -159.3 Million USD | -171.56% |
| 2014 | -56.15 Million USD | -154.77% |
| 2013 | -24 Million USD | -0.63% |
| 2012 | -23.41 Million USD | -62.26% |
| 2011 | -14.91 Million USD | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q1 | -49.47 Million USD | -342.71% |
| 2024 Q2 | -59.39 Million USD | -20.04% |
| 2023 Q3 | -84.72 Million USD | -0.48% |
| 2023 Q2 | -84.32 Million USD | 0.2% |
| 2023 Q1 | -84.49 Million USD | -432.19% |
| 2023 Q4 | -8.69 Million USD | 89.74% |
| 2023 FY | - USD | 39.7% |
| 2022 Q3 | -88.17 Million USD | 4.96% |
| 2022 FY | - USD | 48.6% |
| 2022 Q2 | -92.77 Million USD | 22.25% |
| 2022 Q1 | -119.33 Million USD | 10.72% |
| 2022 Q4 | 25.43 Million USD | 128.84% |
| 2021 Q3 | -170.52 Million USD | 27.36% |
| 2021 Q4 | -133.66 Million USD | 21.62% |
| 2021 FY | - USD | 15.2% |
| 2021 Q2 | -234.75 Million USD | -4.28% |
| 2021 Q1 | -225.11 Million USD | -9.42% |
| 2020 Q3 | -186.4 Million USD | -654.51% |
| 2020 Q1 | -204.76 Million USD | 10.06% |
| 2020 Q2 | -24.7 Million USD | 87.93% |
| 2020 FY | - USD | 21.42% |
| 2020 Q4 | -205.73 Million USD | -10.37% |
| 2019 FY | - USD | -42.99% |
| 2019 Q1 | -166.79 Million USD | -9.27% |
| 2019 Q2 | -198.22 Million USD | -18.84% |
| 2019 Q4 | -227.66 Million USD | -11.46% |
| 2019 Q3 | -204.26 Million USD | -3.05% |
| 2018 FY | - USD | -69.87% |
| 2018 Q4 | -152.64 Million USD | -5.05% |
| 2018 Q3 | -145.31 Million USD | -0.97% |
| 2018 Q2 | -143.91 Million USD | -24.53% |
| 2018 Q1 | -115.56 Million USD | 2.26% |
| 2017 Q3 | -74.55 Million USD | -12.41% |
| 2017 FY | - USD | -28.33% |
| 2017 Q2 | -66.32 Million USD | -3.31% |
| 2017 Q1 | -64.2 Million USD | 9.81% |
| 2017 Q4 | -118.23 Million USD | -58.58% |
| 2016 Q2 | -54.7 Million USD | -3.08% |
| 2016 Q1 | -53.07 Million USD | -9.87% |
| 2016 Q3 | -73.55 Million USD | -34.47% |
| 2016 Q4 | -71.18 Million USD | 3.23% |
| 2016 FY | - USD | -59.0% |
| 2015 Q1 | -22.78 Million USD | -18.18% |
| 2015 FY | - USD | -171.56% |
| 2015 Q2 | -46.27 Million USD | -103.1% |
| 2015 Q3 | -42.42 Million USD | 8.33% |
| 2015 Q4 | -48.3 Million USD | -13.86% |
| 2014 FY | - USD | -154.77% |
| 2014 Q3 | -15.31 Million USD | -19.71% |
| 2014 Q4 | -19.28 Million USD | -25.91% |
| 2014 Q1 | -10.19 Million USD | -30.51% |
| 2014 Q2 | -12.79 Million USD | -25.5% |
| 2013 Q2 | -3.63 Million USD | 42.11% |
| 2013 Q4 | -7.81 Million USD | -32.73% |
| 2013 FY | - USD | -0.63% |
| 2013 Q1 | -6.27 Million USD | 28.81% |
| 2013 Q3 | -5.88 Million USD | -61.96% |
| 2012 Q3 | -4.93 Million USD | -8.23% |
| 2012 Q2 | -4.55 Million USD | 11.42% |
| 2012 Q1 | -5.14 Million USD | 0.0% |
| 2012 Q4 | -8.81 Million USD | -78.68% |
| 2012 FY | - USD | -62.26% |
| 2011 FY | - USD | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Editas Medicine, Inc. | -163.11 Million USD | -2.479% |
| Dynavax Technologies Corporation | 9.66 Million USD | 1829.371% |
| Supernus Pharmaceuticals, Inc. | 98.26 Million USD | 270.118% |
| Perrigo Company plc | 646.2 Million USD | 125.868% |
| Illumina, Inc. | -608 Million USD | 72.506% |
| Thermo Fisher Scientific Inc. | 10.8 Billion USD | 101.548% |
| Iovance Biotherapeutics, Inc. | -449.01 Million USD | 62.771% |
| Walgreens Boots Alliance, Inc. | -11.27 Billion USD | 98.518% |
| IQVIA Holdings Inc. | 3.25 Billion USD | 105.134% |
| Heron Therapeutics, Inc. | -103.79 Million USD | -61.054% |
| Regeneron Pharmaceuticals, Inc. | 4.65 Billion USD | 103.592% |
| Unity Biotechnology, Inc. | -37.28 Million USD | -348.357% |
| Waters Corporation | 1.02 Billion USD | 116.352% |
| Biogen Inc. | 2.37 Billion USD | 107.032% |
| Sangamo Therapeutics, Inc. | -87.42 Million USD | -91.201% |
| Evolus, Inc. | -41.81 Million USD | -299.811% |
| Adicet Bio, Inc. | -136.53 Million USD | -22.431% |
| Cara Therapeutics, Inc. | -117.65 Million USD | -42.083% |
| Esperion Therapeutics, Inc. | -150.1 Million USD | -11.36% |
| FibroGen, Inc. | -261.4 Million USD | 36.053% |
| Agilent Technologies, Inc. | 1.67 Billion USD | 109.968% |
| Corbus Pharmaceuticals Holdings, Inc. | -44.43 Million USD | -276.178% |
| Homology Medicines, Inc. | -47.75 Million USD | -250.031% |
| Geron Corporation | -174.78 Million USD | 4.36% |
| Alnylam Pharmaceuticals, Inc. | -228.12 Million USD | 26.723% |
| Amicus Therapeutics, Inc. | -92.07 Million USD | -81.541% |
| Myriad Genetics, Inc. | -67.8 Million USD | -146.55% |
| Viking Therapeutics, Inc. | -100.82 Million USD | -65.79% |
| Intellia Therapeutics, Inc. | -506.31 Million USD | 66.985% |
| Zoetis Inc. | 3.68 Billion USD | 104.536% |
| Abeona Therapeutics Inc. | -50.57 Million USD | -230.541% |
| Mettler-Toledo International Inc. | 1.16 Billion USD | 114.36% |
| BioMarin Pharmaceutical Inc. | 310.28 Million USD | 153.874% |
| Vertex Pharmaceuticals Incorporated | 4.6 Billion USD | 103.63% |
| Kala Pharmaceuticals, Inc. | -36.08 Million USD | -363.281% |
| Ionis Pharmaceuticals, Inc. | -230.01 Million USD | 27.324% |
| Atara Biotherapeutics, Inc. | -265.99 Million USD | 37.157% |
| Verastem, Inc. | -83.16 Million USD | -100.997% |
| Nektar Therapeutics | -243.1 Million USD | 31.24% |
| Axsome Therapeutics, Inc. | -224.99 Million USD | 25.703% |
| Aclaris Therapeutics, Inc. | -87.98 Million USD | -89.988% |
| Sarepta Therapeutics, Inc. | -439.19 Million USD | 61.939% |
| OPKO Health, Inc. | -65.51 Million USD | -155.145% |
| Exelixis, Inc. | 196.6 Million USD | 185.025% |
| Neurocrine Biosciences, Inc. | 416.1 Million USD | 140.173% |
| Corcept Therapeutics Incorporated | 108.32 Million USD | 254.316% |
| Anavex Life Sciences Corp. | -55.75 Million USD | -199.808% |
| uniQure N.V. | -253.1 Million USD | 33.955% |
| Imunon, Inc. | -20.78 Million USD | -704.344% |
| Blueprint Medicines Corporation | -474.61 Million USD | 64.779% |
| Insmed Incorporated | -654.73 Million USD | 74.469% |
| Halozyme Therapeutics, Inc. | 451.94 Million USD | 136.987% |
| Agios Pharmaceuticals, Inc. | -345.46 Million USD | 51.613% |
| TG Therapeutics, Inc. | 26.1 Million USD | 740.464% |
| Incyte Corporation | 919.42 Million USD | 118.181% |
| Emergent BioSolutions Inc. | -505.29 Million USD | 66.918% |